

CEE Equity Research | Insurance | Hungary 03 March 2023

CIG Pannonia

Recommendation: BUY (unch.)

Target price (e-o-y): HUF 410 (unch.)

Share price: HUF 297

Share price as of 03/03/2023	HUF 297
Number of diluted shares [million]	94.4
Market capitalization [HUF mn/EUR mn]	28,045 / 74.0
Daily turnover 12M [HUF million]	0.02
Bloomberg	PANNONIA HB
Reuters	CIGP.BU
Free float	42.65%
52 week range	HUF 250 - 350




Adjusted Q4/22 results were as strong as posssible

- Equity Analyst
 Attila Vágó
 +361 489 2265
 a.vago@con.hu
- Alkotas Point 55-61 Alkotás utca, H-1123 Budapest www.con.hu
- CIG Pannonia (Pannonia) consolidated after-tax profit of HUF 383mn for Q4/2022. Adjusted for the impact of extra insurance tax of HUF 324mn, after-tax profit was HUF 707mn on our estimate (+555% YoY and +76% QoQ) on GWP coming in at HUF 9.7bn (+29% YoY). Total reported comprehensive profit amounted to HUF 1.4bn in Q4/22 versus losses of HUF 1.2bn in the same period of last year despite a rising yield environment.
- Life insurance segment had after-tax profit of HUF 0.5bn compared to HUF 0.3bn in Q4/21, while non-life business also generated losses of HUF 241 mn as against losses of HUF 0.2bn in the same period a year earlier due to the cost of aggressive expansion. Other activities remained in the black, with after tax profit of HUF 0.4bn compared to after-tax profit of HUF 0.3bn in Q4/21. Elimination amounted to HUF 0.2bn vs. HUF 1.7bn in the base period.
- Despite rapid cost inflation and rising yields, Pannonia's businesses remained financially stable and fundamentally solid: the consolidated solvency II capital adequacy ratio stood at as high as 206% at the end of December, compared with 200% at the end of last September and 273% at the end of 2021.
- In 2022, Pannonia reached reported after-tax profit of HUF 1.2bn (-28% YoY), while after adjusting for the net impact of extra taxes (of HUF 0.6bn) after-tax profit was HUF 1.8bn (+31% YoY taking into account of the positive impact of provision release of HUF 0.3bn in 2021) on GWP of HUF 32.3bn compared to HUF 22.7bn in 2021.
- In 2022, results were mainly driven by rapid GWP growth (+42% YoY) primarily in UL, CASCO, industrial property insurances and other non-life products. UL products and single life premium products sales and profitability were weaker as yields and insurance taxes increased, while the considerable increase (+64% YoY) in commission led by new business sales growth and cost inflation also put temporarily a drag on results, which however were partly compensated for by i) a decrease in



- reserves mainly for single-fee UL products, ii) accounting reserves for traditional products, iii) lower reserves for Italian surety products, and higher interest income (the latter increased by HUF 0.6bn YoY).
- As in the previous quarter, CASCO products of industrial assets and fleet increased significantly in Q4/22, by HUF 2 and 2.7bn, respectively, compared to the same period of 2021. Pannonia almost doubled new acquisitions of group life products in one year, while new acquisitions of other non-life products almost tripled. The insurer was also able to increase the new procurement of traditional products, though to a lesser extent compared to the previous quarters. New business sales were supported by strong sales network, independent sales channels, in particular, by which fee income increased more than three times compared to 2021.
- At the Group level, premium arising from new group product contracts in Q4/22 (+81% YoY) was primarily driven by the sales contracts with larger companies, while unit-linked products saw a 7% decline YoY (mainly due to rising yields). New traditional life insurance products sales remained broadly flat (+3% YoY), while non-life segment saw a stunning increase in GWP, albeit from a very low base, particularly CASCO and corporate property insurances.



New business sales breakdown by products (HUF mln)

Source: CIG Pannonia, Concorde's estimate

As a whole, life insurance GWP rose by 20% YoY in Q4//22 from HUF 6.5bn to HUF 7.8bn. Total unit-linked life insurance amounted to HUF 5.5bn (thereof 38%, ie. HUF 2.1bn was pension insurance policies), HUF 2.1bn were traditional life products (thereof HUF 0.3bn came from pension insurance policies and HUF 1.8bn were health insurance policies). Non-life GWP increased by 484% YoY, albeit from a low base, as a result of aggressive sales campaign mainly through Bankholding's branch network.




Breakdown of the Group's GWP and after tax profit (HUF mln)

	Life		Non-life		Other		Cons.		Total	
					20	22				
	Q1-4	Q4	Q1-4	Q4	Q1-4	Q4	Q1-4	Q4	Q1-4	Q4
GWP	26 834	7 838	5 512	1 846	0	0	0	0	32 346	9 684
Reported after-tax profit	1 484	483	-815	-241	-360	372	902	-231	1 211	845
After-tax adjustments	0	0	0	0	0	0	0	0	0	0
Adjusted after-tax profit	1 484	483	-815	-241	-360	372	902	-231	1 211	845
Reported total comprehensive income	-2 247	1 132	-893	81	-360	372	902	-231	-2 598	1 816
Change in adj. after-tax profit (YoY)	28%	86%	15%	42%	n.a.	225%	n.a.	n.a.	154%	n.a.
Change in GWP (YoY)	22%	20%	771%	484%	n.a.	n.a.	n.a.	n.a.	18%	20%
	Life		Non-life		Other		Cons.		Total	
				20	21					
	Q1-4	Q4	Q1-4	Q4	Q1-4	Q4	Q1-4	Q4	Q1-4	Q4
GWP	22 080	6 542	633	316	0	0	0	0	22 713	6 858
Reported after-tax profit	1 161	259	-703	-173	140	299	1 084	1 666	1 682	-1 281
After-tax adjustments	0	0	3	0	0	0	0	0	3	0
Adjusted after-tax profit	1 161	259	-706	-170	140	299	1 084	1 666	1 679	-1 278
Reported total comprehensive income	-1 031	-1 283	-887	-275	140	299	1 084	1 666	-694	-2 925
	Life		Non-life		Other		Cons.		Total	
				20	20					
	Q1-4	Q4	Q1-4	Q4	Q1-4	Q4	Q1-4	Q4	Q1-4	Q4
GWP	19 104	5 638	215	76	0	0	0	0	19 319	5 714
Reported after-tax profit	717	-167	-759	-903	380	92	322	-582	16	-396
After-tax adjustments	0	0	0	0	0	0	0	0	0	0
Adjusted after-tax profit	717	-167	-759	-555	380	92	322	-582	660	-48
Reported total comprehensive income	384	350	-802	-838	380	92	322	-582	284	186

Source: CIG Pannonia, Concorde's estimate

Life segment benefited mostly from the increase in top-up and single premium income as well as growing income from renewals. GWP from renewals amounted to HUF 4.5bn in Q4/22 (+6% YoY). GWP from the first annual premiums of policies sold was HUF 1.8bn (+237% YoY), and top-up and single premiums came in at HUF 1.6bn (+109% YoY), accounting for 21% of total life insurance GWP in Q4/22 compared to 23% YoY. The renewal ratio declined from 96% to 90% QoQ and from 100% YoY lower propensity of households to save in insurance products amid a rising yield environment and rapid inflation.

GWP breakdown in the life insurance segment (HUF bln)



Source: Pannonia, Concorde estimate.

• Investment results were positive at HUF 1.1bn in Q4/22 compared to HUF 2.1bn YoY as a result of rising bond yields and stock prices in the global stock markets.


- The total operating cost of the Issuer was HUF 3.5bn in Q4/22, of which HUF 2.2bn was related to the fees, commissions and other acquisition costs (+46% YoY), and HUF 0.7bn was related to other operating costs (+20% YoY) and another HUF 0.6bn was other expenses (+457% YoY). Acquisition costs show a significantly increasing trend overall, driven by fast-growing non-life new business sales, following the development and recruitment of new business lines, organizations and employees, and the related implementation of Pannonia's medium-term growth strategy. Life acquisition costs remained broadly unchanged YoY, while in the non-life segment acquisition costs jumped by 600% YoY.
- Consolidated net claims and related settlement expenses rose by 5% YoY in Q3/22 due to the combined impact of lower life segment claims expenditures in the wake of the lower number of surrenders of unit-linked products, while traditional and group claims increased, but less than the decrease in unit-linked repurchases, and higher claims in non-life business in line with inflation and business expansion.

The net decrease in insurance reserves was mainly attributed to decrease in reserves for single-fee UL products and accounting reserves for traditional products.

 12-month rolling GWP appeared to have kept on increasing thanks to higher top-up income and fast-growing new life and non-life business sales.


Quarterly consolidated GWP breakdown (HUF bln)

12-m rolling GWP breakdown (HUF bln)



Source: Pannonia, Concorde estimate

• All sales channels increased their sales volume, with the banking channel (Bankholding) generating an outstanding 150% YoY growth in Q4/22 followed by independent brokers which delivered 68% YoY growth, supported by newly launched products in line with the new growth-driven business strategy. Pannonia concluded a framework agreement with the Hungarian Bankholding Group (Bankholding) for a period of 20 years, according to which Bankholding Group member banks, ie. MKB Bank, Budapest Bank and Takarékbank, will sell exclusively the life and non-life insurance products of the CIG Pannonia Group.



Source: Pannonia, Concorde estimate

Outlook

- We reiterate CIG Pannonia (Pannonia) as BUY, as well as our 12-m target price at HUF 410, which leaves a 38% upside potential from the current share price.
- We leave our net income forecasts for 2023 and 2024 unchanged at HUF 1.56bn and HUF 2.04bn, respectively, which reflect the harmful impact of 1) a substantial increase in insurance ("windfall") tax imposed on Hungarian insurers for the period between 1 July 2022 and 31 December, 2023, and 2) recession as an consequence of the severe energy crisis in Europe and rising yields.
- Consequently, EPS may come in at HUF 17 in 2023 and then to grow again by 31% to HUF 22 in 2024. Dividend will inevitably drop compared to previous year's payment, albeit from an unsustainably high level, to ca. HUF 11 a share for 2022, implying a DIVY of 4% based on the current share price.
- We remain confident that Pannonia's resilient and flexible organization can weather the impending economic slowdown, rather than being overwhelmed by it, while remaining committed to market expansion and product innovation.



Disclaimer

Concorde Securities Ltd. does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interests that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. For analysts' certification and other important disclosures, please refer to the "Disclaimer" section at the end of this report.

DISCLAIMER I.

This research report has been prepared by Concorde Securities Ltd., a full-service Hungarian investment banking, investment management and brokerage firm. Concorde Securities Ltd. is under the supervision of the National Bank of Hungary in its capacity as financial supervisory authority.

Concorde Securities Ltd. is registered in Hungary and does not have any subsidiaries, branches or offices outside of Hungary. Therefore we are not allowed to provide direct investment banking services to US investors and restrictions may apply to our potential investment banking services according to your country's jurisdiction.

Our salespeople, traders and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are their own and may be contrary to the opinions expressed in our research products, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed by our analysts or traders.

Our research, sales and trading professionals are paid based on the profitability of the respective divisions of Concorde Securities Ltd., which from time-to-time may include revenues from the firm's capital market activity. Concorde Securities Ltd. does not prohibit analysts, salespeople and traders from maintaining a financial interest in the securities or futures of any companies that they cover or trade on their clients' behalf in strict compliance with the Hungarian Capital Markets Act.

ANALYSTS CERTIFICATION

The research analysts undersigned and responsible for the preparation of this report hereby certify that (i) the views expressed in this research report accurately reflect their personal views about any and all of the securities or issuers referred to in this research report; (ii) no part of the analysts' compensation was, is or will be directly or indirectly related to the specific recommendation or views expressed in this report and (iii) no part of their compensation is tied to any specific investment transactions performed by Concorde Securities Ltd.

Name and job title of individuals involved in the production of this report are disclosed at the end of this report.

Concorde Securities Ltd. is a leading manager and underwriter of Hungarian equity offerings. We have investment banking and other business relations with a substantial percentage of the companies traded on the Budapest Stock Exchange and covered by our research department. Concorde Securities Ltd, its directors and employees may have a position in these securities, which may change at any time.

Concorde Securities Ltd. acted as Lead Manager of the private and public share placement of the shares of FHB in 2003, Masterplast in 2012 and Duna House in 2016. Concorde Securities Ltd. acted as the Co-lead Manager of Gedeon Richter's exchangeable bond issue in September 2004. Concorde Securities Ltd. has provided financial advice to Magyar Telekom.

EXPLANATION OF RATINGS AND METHODOLOGY

Rating	Trigger
Buy	Total return is expected to exceed 20% in the next 12 months
Accumulate	Total return is expected to be in the range of 10-20%
Neutral	Total return is expected to be in the range of 10%-(-10%)
Reduce	Total return is expected to be in the range of -10-(-20%)
Sell	Total return is expected to be lower than -20%
Under Revision	The stock is put Under Revision if the covering analyst considers new information may change the valuation materially and if this may take more time.



Coverage in transition

Coverage in transition rating is assigned to a stock if there is a change in analyst.

Securities prices:

Prices are taken as of the previous day's close on the home market unless otherwise stated.

Valuations and risks:

Analysis of specific risks to set stock target prices highlighted in our investment case(s) are outlined throughout the report. For details of methodologies used to determine our price targets and risks related to the achievement of the targets referred to in the main body of the report or at Rating Methodology on our website, visit (https://www.con.hu/wp-content/uploads/2016/04/Methodology_concorde_research.pdf?tstamp=201710021038)

Research disclosures:

Concorde Securities Ltd. may have published other investment recommendations in respect of the same securities/instruments recommended in this report during the preceding 12 months. Disclosure of previous investment recommendations produced by Concorde Securities Ltd. in the previous 12 months can be found at Rating history. (https://www.con.hu/wp-content/uploads/2016/04/Rating-history.pdf?tstamp=201710021038)

GFNFRAI

This report is provided for information purposes only and does not represent an offer for sale, or the solicitation of any offer to buy or sell any securities.

The information, and any opinions, estimates and forecast have been obtained from sources believed by us to be reliable, but no representation or warranty, express or implied is made by us as to their accuracy or completeness. The information, opinions, estimates and forecasts may well be affected by subsequent changes in market conditions. This document may not be reproduced in whole or in part, or published for any purpose.

REPRODUCTION OR REBROADCAST OF ANY PORTION OF THIS RESEARCH REPORT IS STRICTLY PROHIBITED WITHOUT THE WRITTEN PERMISSION OF CONCORDE SECURITIES LTD.

DISCLAIMER II.

This research/commentary was prepared by the assignment of Budapest Stock Exchange Ltd. (registered seat: 1054 Budapest, Szabadság tér 7. Platina torony I. ép. IV. emelet; company registration number: 01-10-044764, hereinafter: BSE) under the agreement which was concluded by and between BSE and Concorde Securities Ltd. (registered seat: H-1123 Budapest Alkotás utca 50., company registration number: 01-10-043521, hereinafter: Investment Service Provider)

BSE shall not be liable for the content of this research/commentary, especially for the accuracy and completeness of the information therein and for the forecasts and conclusions; the Service Provider shall be solely liable for these. The Service Provider is entitled to all copyrights regarding this research/commentary however BSE is entitled to use and advertise/spread it but BSE shall not modify its content.

This research/commentary shall not be qualified as investment advice specified in Point 9 Section 4 (2) of Act No. CXXXVIII of 2007 on Investment Firms and Commodity Dealers and on the Regulations Governing their Activities. Furthermore, this document shall not be qualified as an offer or call to tenders for the purchase, sale or hold of the financial instrument(s) concerned by the research/commentary.